Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Viral Hepatitis

Quick Links

Veterans Crisis Line Badge
My healthevet badge

FAQ: Is it true the FDA approved new drugs for hepatitis C?

for Veterans and the Public

Frequently Asked Questions

Q: Is it true the FDA approved new drugs for hepatitis C?

Yes. In late 2013, the US Food and Drug Administration (FDA) approved two new drugs for hepatitis C.

Simeprevir (Olysio) is a tablet to be taken once per day along with pegylated interferon and ribavirin for patients with genotype 1.

Sofosbuvir (Sovaldi) is a tablet to be taken once per day.

  • with pegylated interferon and ribavirin for genotype 1
  • with ribavirin only (no interferon) for genotype 2 and 3
  • in some patients with genotype 1 who are not able to take interferon, some can take sofosbuvir with ribavirin (without interferon).

The combination of simeprevir and sofosbuvir (used together) is not FDA approved. However, in very limited situations, it may be considered by your provider. This regimen consists of simeprevir with sofosbuvir and with or without ribavirin. No interferon is used in this regimen. Again this is used only in a limited number of situations.

There are also multiple other new drugs under investigation and some of which may be approved in 2014-2015.